Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Analysts had expected sales of $2.08 billion. Eli Lilly raised its annual profit forecast by $1.30 per share to a range of $13.50 to $14 per share. The drugmaker also bumped its annual forecast by $2 ...
said CEO David Ricks. Eli Lilly & Co. (LLY) posted stronger-than-expected fourth quarter earnings Thursday, while lifting its full-year profit forecast, as sales of its blockbuster diabetes ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit Rapidly climbing sales of the ...
(RTTNews) - Eli Lilly And Co. (LLY) revealed earnings for its first quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled $2.24 ...
Eli Lilly (LLY) has reported a better-than-expected first-quarter profit and raised its forward guidance as sales of its popular weight-loss drugs accelerate. The pharmaceutical giant reported ...
Soaring sales of Eli Lilly’s hugely popular diabetes and weight-loss drugs Mounjaro and Zepbound prompted the US pharmaceutical group to lift its guidance for the year and pushed its share price ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...